CN101022806A - (4-烷基哌嗪基)(苯基)甲酮在治疗阿尔茨海默病中的应用 - Google Patents

(4-烷基哌嗪基)(苯基)甲酮在治疗阿尔茨海默病中的应用 Download PDF

Info

Publication number
CN101022806A
CN101022806A CNA2005800194203A CN200580019420A CN101022806A CN 101022806 A CN101022806 A CN 101022806A CN A2005800194203 A CNA2005800194203 A CN A2005800194203A CN 200580019420 A CN200580019420 A CN 200580019420A CN 101022806 A CN101022806 A CN 101022806A
Authority
CN
China
Prior art keywords
alkyl
chemical compound
effective
procaine
alkoxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800194203A
Other languages
English (en)
Chinese (zh)
Inventor
L·勒卡努
J·格里森
V·帕帕多普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Georgetown University
Samaritan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, Samaritan Pharmaceuticals Inc filed Critical Georgetown University
Publication of CN101022806A publication Critical patent/CN101022806A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800194203A 2004-04-15 2005-04-12 (4-烷基哌嗪基)(苯基)甲酮在治疗阿尔茨海默病中的应用 Pending CN101022806A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56264304P 2004-04-15 2004-04-15
US60/562,643 2004-04-15

Publications (1)

Publication Number Publication Date
CN101022806A true CN101022806A (zh) 2007-08-22

Family

ID=35058789

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800194203A Pending CN101022806A (zh) 2004-04-15 2005-04-12 (4-烷基哌嗪基)(苯基)甲酮在治疗阿尔茨海默病中的应用

Country Status (7)

Country Link
US (1) US20090197891A1 (cg-RX-API-DMAC7.html)
EP (1) EP1755605A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007532649A (cg-RX-API-DMAC7.html)
CN (1) CN101022806A (cg-RX-API-DMAC7.html)
AU (1) AU2005240991A1 (cg-RX-API-DMAC7.html)
CA (1) CA2564068A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005108378A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329282A (zh) * 2018-01-16 2018-07-27 新乡医学院 一种苯基哌嗪类衍生物及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2022246115A1 (en) * 2021-05-19 2022-11-24 Cornell University Apt1 and apt2 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2304155A1 (de) * 1973-01-29 1974-08-01 Ichthyol Ges Cordes Hermanni & N-acylierte substituierte piperazinbzw. homopiperazinderivate, sowie verfahren zu ihrer herstellung
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1628649A4 (en) * 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108329282A (zh) * 2018-01-16 2018-07-27 新乡医学院 一种苯基哌嗪类衍生物及其制备方法和应用
CN108329282B (zh) * 2018-01-16 2022-01-07 新乡医学院 一种苯基哌嗪类衍生物及其制备方法和应用

Also Published As

Publication number Publication date
JP2007532649A (ja) 2007-11-15
WO2005108378A2 (en) 2005-11-17
AU2005240991A1 (en) 2005-11-17
CA2564068A1 (en) 2005-11-17
WO2005108378A3 (en) 2006-01-12
US20090197891A1 (en) 2009-08-06
EP1755605A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
JP2026053405A (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
US20090286876A1 (en) Neuroprotective benzoate and benzamide compounds
JP6745726B2 (ja) 中枢神経系障害の処置における2,4−チアゾリジンジオン誘導体
JP7439018B2 (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
US12029731B2 (en) Acyl benzo[d]thiazol-2-amine and their methods of use
CN107530323B (zh) 依替福辛的氘化类似物、其衍生物及它们的用途
US20090197891A1 (en) Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
EP0858996A1 (en) Nerve cell protective agents
US20150274742A1 (en) Treating Brain Cancer using Agelastatin A (AA) and Analogues Thereof
WO2009155402A1 (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
CN109824637B (zh) 一种茚酮查尔酮氨基甲酸酯类化合物及其制备方法和用途
US20180263972A1 (en) Analogs of deutetrabenazine, their preparation and use
US20160102058A1 (en) Fluoro-perhexiline compounds and their therapeutic use
US11590089B2 (en) Beta-2 selective adrenergic receptor agonists
JPWO2005079845A1 (ja) 片頭痛予防薬
CN110272349B (zh) 一种2’-羟基-3苯基苯丙酮化合物及其制备方法和用途
KR20110074574A (ko) 1-부틸-2-히드록시아르알킬 피페라진 유도체 및 항-우울증제로서의 그 용도
US11396516B2 (en) Tricyclic compounds as Cyp1 inhibitors
WO2011136192A1 (ja) イミダゾ[1,2-a]ピリジン誘導体
US20150232456A1 (en) Aurora kinase inhibitors
RU2266115C2 (ru) Оптически активные изомеры кетотифена и их терапевтически активные метаболиты
JPH02258749A (ja) ポリヒドロキシベンジルオキシプロパノールアミン
MXPA04012602A (es) Diazocicloalcanos n, n-disustituidos utiles para el tratamiento de trastornos del sistema nervioso central debidos a disfunciones serotonergica.
KR20260064237A (ko) S1pr1과 s1pr4에 대한 기능적 저해제로서의 신규 화합물
WO2026102446A1 (en) Calcium channel modulators and methods of using thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070822